Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) Director Robert J. Kammer sold 10,000 shares of Imprimis Pharmaceuticals stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $3.00, for a total value of $30,000.00. Following the completion of the transaction, the director now owns 919,827 shares in the company, valued at approximately $2,759,481. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of IMMY traded up $0.03 during trading hours on Wednesday, hitting $3.01. The company had a trading volume of 81,700 shares, compared to its average volume of 256,188. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 3.66. Imprimis Pharmaceuticals Inc has a 52-week low of $1.35 and a 52-week high of $3.39.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its quarterly earnings data on Monday, August 6th. The specialty pharmaceutical company reported $0.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.24. The firm had revenue of $10.38 million for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 372.57% and a negative net margin of 28.59%.
Separately, ValuEngine upgraded Imprimis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd.
Several institutional investors and hedge funds have recently added to or reduced their stakes in IMMY. Northern Trust Corp increased its holdings in shares of Imprimis Pharmaceuticals by 145.8% in the first quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 39,750 shares during the period. Birchview Capital LP bought a new stake in shares of Imprimis Pharmaceuticals in the second quarter worth about $396,000. Granite Investment Partners LLC grew its stake in shares of Imprimis Pharmaceuticals by 153.8% in the second quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock worth $376,000 after purchasing an additional 103,607 shares during the last quarter. Finally, Ardsley Advisory Partners grew its stake in shares of Imprimis Pharmaceuticals by 42.9% in the second quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $220,000 after purchasing an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 8.62% of the company’s stock.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.
Further Reading: Return on Investment (ROI)
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.